Compare Sasol Ltd. American Depositary Shares (SSL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sasol Ltd. American Depositary Shares vs TG Therapeutics Inc — how do they compare? Sasol Ltd. American Depositary Shares trades at $15.19 (market cap $9.69B), while TG Therapeutics Inc trades at $54.85 (market cap $8.16B). The key difference: Sasol Ltd. American Depositary Shares is the larger of the two by market cap, and Sasol Ltd. American Depositary Shares is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sasol Ltd. American Depositary Shares for 0 Days and TG Therapeutics Inc for 15 Days on average.
| SSL | TGTX | |
|---|---|---|
Market Cap | $9.69B | $8.16B |
Volume | 2,297,057 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $15.14 | $59.06 |
52-Week Low | $5.33 | $26.94 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $13.39B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $52.95, up 1.46% on the day, with a bearish technical signal from moving averages despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29 million and net income of $447.18 million, though recent quarterly EPS results have missed expectations. Analyst sentiment remains largely positive, with an 84.62% buy rating and a consensus price target of $80.50, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook for TGTX is mixed, with robust revenue guidance and product momentum offset by earnings misses and negative cash flow. Key opportunities include BRIUMVI's expanding market share and potential buyout speculation, but risks involve ongoing legal scrutiny, competitive pressures, and the need to translate top-line growth into consistent bottom-line performance amid significant cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sasol Ltd. American Depositary Shares
Sasol Limited is a Johannesburg-headquartered chemicals and energy company that uses its proprietary Fischer-Tropsch technology to convert coal, natural gas, and crude-oil feedstocks into fuels and chemical products such as polymers, solvents, surfactants, and ammonia, with operations across Southern Africa and international chemical manufacturing sites, including in US.
Read more on SSL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
